Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes
Marion Lanier1, Derek C Cole1, Yelena Istratiy1
1Medicinal Chemistry - Gastrointestinal Drug Discovery Unit, ‡Structural Biology & Biophysics, §Modeling & Simulation-Global DMPK, Gastrointestinal Drug Discovery Unit, Takeda California, Inc. , 10410 Science Center Drive, San Diego, California 92121, United States.
Journal of Medicinal Chemistry
|June 1, 2017
Summary
Boronic acids effectively inhibit serine hydrolases. Repurposing diverse boronic acid fragments as a targeted library yielded potent enzyme inhibitors, demonstrating utility against autotaxin, a cardiovascular disease target.
Area of Science:
- Biochemistry and Medicinal Chemistry
- Enzyme Inhibition
- Drug Discovery
Background:
- Serine hydrolases are a significant class of enzymes.
- Boronic acids are known reversible inhibitors of serine hydrolases.
- Boronic acids are widely available due to their use in coupling chemistry.
Purpose of the Study:
- To repurpose a collection of boronic acid fragments as a targeted library for serine hydrolases.
- To identify potent inhibitors of serine hydrolases using this fragment library.
- To demonstrate the utility of this approach against autotaxin, a phospholipase linked to cardiovascular disease.
Main Methods:
- Assembled a library of approximately 650 chemically diverse boronic acid fragments.
- Screened the library against serine hydrolases and related enzymes.
- Evaluated inhibitor efficiency using Lipinski's Rule of Three (LE > 0.6).
Main Results:
- Identified highly efficient inhibitor 'hits' (LE > 0.6) from the boronic acid fragment library.
- Demonstrated successful application of the approach against autotaxin.
- Validated the strategy for discovering potent serine hydrolase inhibitors.
Conclusions:
- Repurposing commercially available boronic acid fragments is an efficient strategy for targeting serine hydrolases.
- This directed fragment-based approach yields potent inhibitors.
- The method is applicable to enzymes of therapeutic interest, such as autotaxin in cardiovascular disease.


